



HAL
open science

Pharmacology and pharmacovigilance of protein kinase inhibitors

Charles Khouri, Julien Mahé, Laura Caquelin, Clara Locher, Fabien Despas

► **To cite this version:**

Charles Khouri, Julien Mahé, Laura Caquelin, Clara Locher, Fabien Despas. Pharmacology and pharmacovigilance of protein kinase inhibitors. *Thérapies*, 2022, 77 (2), pp.207-217. 10.1016/j.therap.2021.11.004 . hal-03513883

HAL Id: hal-03513883

<https://hal.science/hal-03513883>

Submitted on 14 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

THERAPIES

HEADING: Hemato-oncopharmacology

Pharmacology and pharmacovigilance of protein kinase inhibitors

Pharmacology and pharmacovigilance of protein kinase inhibitors

Charles Khouri^{a,b,†}, Julien Mahé^{c†}, Laura Caquelin^d, Clara Locher^d, Fabien Despas^{e,*}

^a *Pharmacovigilance Department, Grenoble Alpes University Hospital, 38000 Grenoble, France*

^b *Univ. Grenoble Alpes, INSERM UMR 1300 – HP2 Laboratory, 38000 Grenoble, France*

^c *Department of Pharmacology, Regional Pharmacovigilance Center, CHU Nantes, 44093 Nantes, France*

^d *Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), 35000 Rennes, France*

^e *Department of Medical and Clinical Pharmacology, Inserm 1297, CIC 1436, Faculty of Medicine, CHU de Toulouse, University Paul-Sabatier, 31000 Toulouse, France*

Received 12 October 2021; accepted 31 October 2021

***Corresponding author.** Department of Medical and Clinical Pharmacology, INSERM 1027, Faculty of Medicine, CHU, University Paul Sabatier, 31000 Toulouse, France.

E-mail address: fabien.despas@univ-tlse3.fr (F. Despas).

[†]Charles Khouri and Julien Mahé equally participated to the study.

Abstract

Protein kinase inhibitors experienced their advent in the 2000s. Their market introduction made it possible to constitute the class of targeted therapies administered orally. This name was chosen to mark a break with conventional chemotherapy drugs, but it is important to stress that these are multi-target drugs with complex affinity profiles. Adverse effects can be explained by direct interactions with their targets of interest, chosen for their indications (on-target) but also interactions with other targets (off-target). The adverse effect profiles of these drugs are therefore varied and it is possible to identify common profiles related to inhibitions of common targets. Identification of these targets has improved the global understanding of the pathophysiological mechanisms underlying the onset of adverse drug reactions as well as of the related diseases, and makes it possible to predict the adverse effect profile of new protein kinase inhibitors based on their affinities. In this review, we describe the main adverse drug reactions associated with protein kinase inhibitors, their frequency and their plausible mechanisms of action.

KEYWORDS

Protein kinases inhibitors; Pharmacovigilance; On- and off-target

Abbreviations

ABL: Abelson proto-oncogene

ADR: adverse drug reaction

AGC: PKA, PKG, and PKC family kinases

ALK: anaplastic lymphoma kinase

ALP: alkaline phosphatase

ALT: alanine transaminase

aRR: adjusted rate ratio

AST: aspartate transaminase

ATP: adenosine triphosphate

BCR-ABL: breakpoint cluster region - Abelson

BTK: Bruton's tyrosine kinase

CDK4/CDK6: cyclin-dependent kinases

CMGC: CDK/MAPK/GSK/CDK-like kinase group

CSK: c-terminal Src kinase

EGFR: epidermal growth factor receptor

EMA: European Medicines Agency

FDA: Food and Drug Administration

FLT: fms-like tyrosine kinase

ILD: interstitial lung disease

JAK: Janus kinase

MAPK: mitogen-activated protein kinases

MEK1/MEK2: mitogen-activated protein kinase

mTOR: mammalian target of rapamycin

PAH: pulmonary arterial hypertension

PDGFR: platelet-derived growth factor receptors

PKC: protein kinase C

PKI: protein kinase inhibitor

SmPCs: summaries of product characteristics

STE: ste20 kinases

SyK: spleen tyrosine kinase

VEGFR: vascular endothelial growth factor receptor

WHO: World Health Organisation

Protein kinases in the living world

Protein kinase enzymes are fundamental enzymes in the living world. The functions performed are ubiquitous and largely preserved in the different kingdoms of life, especially in plants and animals. For example, the number is: 1792 kinases in the genome of the rice grain (*Oryza sativa*), 454 for the nematode worm (*Caenorhabditis elegans*), 240 kinases for the fruit fly (*Drosophila melanogaster*) and 518 kinases for the human genome (*Homo sapiens*). Also, among the human genome representing 30,000 genes, around 1.7% codes for protein kinases. The biochemical principle of this class of enzyme is to catalyse the transfer of a phosphate radical from adenosine triphosphate (ATP) to a hydroxyl group of a protein to change its status from an inactive state to an active state. Enzymes catalysing this type of reaction are mostly substrates of another kinase, thus forming enzymatic cascades with an ability to mediate intracellular messages from the cytoplasmic membrane to the nucleus with the ability to modify the promotion of certain genes. Therefore, there are transmembrane proteins known as receptors (*e.g.* vascular endothelial growth factor [VEGFR], epidermal growth factor receptor [EGFR], platelet-derived growth factor receptors [PDGFR]) and intracytosolic proteins (*e.g.* mitogen-activated protein kinases [MAPK], Bruton's tyrosine kinase [BTK], anaplastic lymphoma kinase [ALK]). Protein kinases –that could be visualized on the kinome phylogenetic tree (Fig. 1)– are classified according to (i) the target amino acid they phosphorylate (*i.e.* serine, threonine or tyrosine) and (ii) the percentage of sequence homology of the amino acid sequences. Of the 518 kinases encoded within the human genome, 478 (92%) are classified as typical kinases –among which 388 (75%) are protein serine-threonine kinases and 90 (17%) are protein tyrosine kinases– and 40 (8%) are classified as atypical kinases [1]. Therefore, it is important to emphasize that kinase enzymes are not limited to tyrosine kinases but much more broadly to protein kinases.

Pharmacological agents that inhibit protein kinases

Protein kinase inhibitor (PKI) drugs have been used for several decades, in particular in drugs that inhibit mTor (-rolimus). However, the advent of this family did not materialize until imatinib was marketed in the early 2000s. Over the past 20 years, in the region of 450 PKIs have at least one clinical trial registered in the clinicaltrials.gov register. Of these inhibitors, almost 100 molecules have been discontinued during their development, due in particular to toxicities, lack of efficacy or commercial reasons. A regulated and updated list of these medicines – with a known International Nonproprietary Name – can be found at <https://www.icoa.fr/pkidb> [2,3]. Currently, more than 60

drugs have been approved for marketing, primarily intended for the treatment of a variety of cancers but also directed against inflammatory diseases [4,5].

Based on data collected from the Cortellis database –a pharmaceutical pipeline database produced by Clarivate Analytics– all kinases targeted by at least one molecule have been represented using the kinome phylogenetic tree in Fig. 1. The tyrosine kinase family is the group for which there has been the most clinical development and the most drugs having obtained a marketing authorization. Kinase targeted by most of the approved drugs is VEGFR, EGFR, KIT, fms-like tyrosine kinase (FLT) and/or Abelson proto-oncogene (ABL). A few marketed drugs target the other groups such as CMGC, AGC and ste20 kinases (STE) family – the targeted kinases are the targeted kinases are cyclin-dependant kinases (CDK4/CDK6), protein kinase C (PKC) and mitogen-activated protein kinases MEK1/MEK2 respectively – but many small molecule kinase inhibitors targeting these families are currently under clinical development. Besides that, inhibition of some on-targets has so far not been successful. Indeed, inhibition of Aurora kinases (AGC family), under evaluation in clinical trials for a dozen molecules, led to many failures for the AKT targets.

Furthermore, small molecule kinase inhibitors are classified based on the region of interaction in the kinase and reversibility of the inhibition. This classification – that described interaction between drug and target(s) – is regularly updated. The drug can be fixed in a reversible orthosteric manner on the ATPase bag, either in an active form of the enzyme (type I) or in an inactive form (type II); some specific subtypes are also described. The interaction can be reversible allosteric on a pocket adjacent to the ATPase site (type III) or on a remote site (type IV). Bivalent inhibitors have been found and can interact on two domains from different regions (type V). Other types are described with irreversible bindings (type VI), especially on cysteine residues, or bindings on two different sites of the protein with the aim of increasing the selectivity of the inhibitor for its preferential target [6,7].

Depending on the modalities of interaction between the drug and its target(s), the notion of selectivity is quite relative. In fact, the ATPase catalytic site is common or even very close in its configuration for a good number of kinases. Finally, a PKI binding to a domain located at a distance from the ATPase catalytic site characterizing the kinases could probably bind to proteins other than the kinase family, but there is little data on this subject in the scientific literature. The affinity profile of PKIs on the human kinome is therefore complex and is now an integral part of the evaluation of drug candidates in the development process. Affinities for targets are quantified and graphical representations allow a better understanding of the ability of a drug to interact with multiple targets (Fig. 2) [8]. For example, dasatinib –a marketed drug for chronic myelogenous leukemia and acute lymphoblastic leukemia– has significant affinity for about 45 different kinases. Sunitinib – a marketed drug for renal adenocarcinoma, gastrointestinal stromal tumours and pancreatic cancer– has

significant affinity for about 69 different kinases. While dasatinib and sunitinib are marketed for very different indications (leukemia *versus* solid tumours), they have 21 protein kinases as common targets [9]. These two drugs not only bind to tyrosine kinase enzymes but also to serine-threonine kinase enzymes. This binding capacity on different targets reflects “on-target effects”, i.e. effects linked to the interaction of the identified target of interest in the management of a disease to be distinguished from the effects referred to as “off-target” which are related to interactions on targets other than that of interest. Several studies have linked the affinity profile of PKIs to adverse reaction profiles [10–14].

We have made the choice not to describe all the types of side effects associated with small molecule protein kinase inhibitors and we have restricted ourselves to the most frequent ones (Fig. 3).

Cardiovascular and metabolic adverse drug reaction

The cardiovascular adverse effects of PKIs were first suggested in 2006 by Kerkela *et al.* They reported *in vitro* and murine experiments suggesting that imatinib caused toxic cardiomyopathy and a single-institution series of 10 patients who developed left ventricular dysfunction on imatinib [15]. However, subsequent prospective studies have not confirmed this first warning and have underlined the difficulty in distinguishing drug-dependent from drug-independent cardiovascular adverse drug reactions (ADRs) given the high incidence of cardiovascular disease in the general population, and even more so in patients suffering from cancer [16]. Indeed, imatinib is now considered to have a favourable metabolic and vascular safety profile [17]. Nevertheless, a number of later generations of PKI marketed in the following years have been linked to a variety of cardiovascular ADRs, from frequent ADRs such as thromboembolic ADRs or arterial hypertension identified in clinical trials, to extremely rare ADRs such as pulmonary arterial hypertension (PAH) identified after drug marketing. The cardio-vascular ADR of cancer therapies and notably from PKI constitute an active area of research because clinicians are faced with a large increase in the number of patients presenting with a combination of cancer, cancer treatment and cancer treatment-related cardiovascular adverse effects due to the longer life expectancy of patients [18,19].

Arterial hypertension

Arterial hypertension is the most common cardio-vascular adverse event of PKI targeting VEGF receptors or their ligands such as pazopanib, sunitinib, sorafenib, ponatinib or apatinib [20,21]. Hypertension is a class effect of VEGF inhibitors and the incidence of hypertension varies depending on the agent used from 30% to 80% of patients [21,22]. Preclinical experiments have shown that the risk of blood pressure elevation with PKI is proportional to the amount of VEGFR2 inhibition [23]. Two main mechanisms for hypertension have been suggested: endothelial dysfunction leading to decreased NO production and stimulation of endothelin-1 pathway, and microvascular rarefaction [24,25]. As a potential consequence, the reporting risk of arterial dissection for which arterial hypertension is the main hypothesized mechanism was further correlated to VEGF inhibition in a pharmacovigilance study using the data from the Food and Drug Administration (FDA) adverse reporting system. This signal remains to be confirmed to date [26,27].

Thromboembolic ADRs

Although patients with malignancies display increased risks of thrombotic ADRs, several retrospective, prospective studies and meta-analyses have shown that arterial and venous thromboembolic ADRs are further increased in cancer patients treated with VEGF inhibitors or with some breakpoint cluster region-Abelson (BCR-ABL) inhibitors such as nilotinib [17,21]. The late onset of these ADRs, associated with the finding that cardiovascular risk factors were common in patients with vascular ADRs in clinical trials, have led to the hypothesis that some PKI may aggravate a pre-existing arteriosclerotic condition and may therefore impact all vascular beds [28]. Indeed, mechanistic studies have indicated that some of these drugs can produce proatherogenic changes, worsen dyslipidemia and hypertriglyceridemia (*e.g.* nilotinib), or have prothrombotic effect through increasing platelet adhesion (*e.g.* ponatinib) [29]. Overall, the higher rates of thrombotic ADRs in those with preexistent atherosclerotic risk factors have led to recommendations that risk factors be addressed in those receiving medications such as ponatinib [30]. For example, preventive strategies with n-acetylcysteine, have been tested in preclinical and early clinical studies but have yet to be prospectively tested in large clinical trials [30].

Bleeding ADRs

On the other hand, bleeding has also been reported in patients with chronic myeloid leukemia using PKIs. Forty percent bleeding frequency was found in patients with chronic myeloid leukemia using dasatinib, with epistaxis and gastrointestinal bleeding as the most specific related bleeding ADRs [31]. Although, chronic myeloid leukemia may be associated with bleeding manifestations due to disease characteristics (platelet dysfunction, thrombocytopenia, acquired von Willebrand disease), it has been shown that some PKI, notably dasatinib, may impair platelet aggregation [32,33].

Cardiomyopathy

PKI induced cardiac failure is one of the most serious cardiac ADR experienced by PKI exposed patients. It can lead to a decrease in left ventricular ejection fraction, contractile dysfunction, hypertensive cardiac remodelling and cardiac ischemia [34]. All the above-described vascular ADRs (*e.g.* arterial and venous thromboembolic ADRs, hypertension) may participate in the genesis of cardiac failure which, for example, has been observed in 2.3% of patients treated by VEGF inhibitors with an OR of 1.35 [1.06 – 1.70] (NNH = 139) in a meta-analysis including 77 phase 3 trials [35,36]. In addition, it has been shown in preclinical studies that inhibition of some protein kinase such as VEGFR or PDGFR may induce cardiotoxicity through a direct action on pericytes, endothelial cells and cardiomyocytes, notably impairing cardiac healing or compensatory mechanisms [36]. Moreover, a pharmacodynamic-pharmacovigilance study mixing disproportionality signals and affinity of PKI for their receptors highlighted the role of ABL protein kinases in cardiac homeostasis and cardiomyocytes survival [11].

Cardiac arrhythmia and QT prolongation

QTc prolongation, have been described with some PKI, notably with pazopanib, sunitinib, imatinib, nilotinib and dasatinib [37]. Based on these observations, *in vitro* studies identified new pathways (non- I_{Kr} -dependent pathways) to QT prolongation, notably with nilotinib through inhibition of the phosphoinositide 3-kinase [38]. Similar effects were observed with the multi-kinase inhibitors dasatinib and sunitinib; all three drugs are classified as ‘possible’ torsade de pointes risk at *crediblemeds.org* [39]. Nevertheless, torsade de pointes and sudden death remains very rare with these drugs [40].

Furthermore, ibrutinib, a Bruton PKI, has been associated with atrial fibrillation since the early drug development phases [41]. To explore the mechanism of ibrutinib related atrial fibrillation an elegant translational study mixing electrophysiology studies, chemoproteomic analysis and pharmacovigilance analysis identified CSK inhibition as a potential mechanism of ibrutinib mediated atrial fibrillation [42]. CSK inhibition is an off-target effect of ibrutinib and may lead to increased inflammation and fibrosis, predisposing the heart to atrial fibrillation [42]. Moreover, an analysis from the World Health Organization pharmacovigilance database described other potential cardiovascular toxicities related to ibrutinib including hypertension, heart failure, ventricular arrhythmias, and conduction disorders with ibrutinib which remains to be further explored [43].

Pulmonary arterial hypertension

Dasatinib, a multi-PKI had been increasingly linked to PAH since 2009 and is now considered to be a definite cause of PAH by the 6th World symposium on pulmonary hypertension [44–46]. More recently, several cases have reported potential association with or deterioration of pre-existing PAH with other PKIs such as bosutinib, ponatinib and lapatinib [13]. Although the underlying mechanism of dasatinib related PAH is still unclear, evidence suggests that SRC and SRC independent mechanisms (through mitochondrial ROS production) are implicated [47–52]. A pharmacodynamics-pharmacovigilance study correlating affinities of PKI for a range of protein kinases and disproportionality values highlighted a possible role of SRC protein kinases as well as other targets, such as TEC whose role remains to be determined [13]. Indeed, given the probable influence of the PKI dosage on the onset of PAH, such secondary targets may also be significant in PAH onset.

Metabolic disorders

Induction of metabolic dysregulation by PKI may largely contribute to the increased risk of cardiovascular diseases. For example, 36% of patients on nilotinib 300 mg twice-a-day experienced hyperglycemia compared with 20% on imatinib [53]. A study of 27 patients also showed a significant increase in total, low-density lipoprotein, and high-density lipoprotein cholesterol within 3 months of treatment [54]. These metabolic ADRs are observed to a lesser extent with all BCR-ABL kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, and ponatinib), while conversely PKI that target VEGF and PDGF signalling pathways (*e.g.* sunitinib and sorafenib) seem to improve glycemia

[55,56]. Although the pathophysiology of these ADRs remains unclear some evidence suggests PI3K inhibition inducing upregulation of the glucose transporter, *glut4*, may be involved [55].

Taken together, the cardiovascular ADRs studies with PKIs made it possible to identify different safety profiles regarding this type of ADRs, probably due to different target profiles [57,58]. These studies have also provided important new insights into vascular biology, physiology, and pathology [59].

Pulmonary ADRs

Pulmonary side effects associated with PKIs are relatively frequent and represent 12.7% of all ADR recorded in Vigibase[®] with this large drug class (request of April 9, 2021). Pleural effusions and interstitial/parenchymal lung disease are the two main pulmonary disorders reported with PKIs.

Pleural effusion

The incidence of pleural effusion with PKIs varies greatly depending on the molecule, with the most data in the literature being for BCR-ABL protein kinase inhibitors (PKIs).

Between 10% and 27% of patients treated with dasatinib in clinical trials developed pleural effusions, most often exudative and lymphocyte predominant with an increased incidence between the 24th and 36th months of treatment [60–63]. Dasatinib dose schedule is a risk factor for pleural effusion and posology of 100 mg once daily had a better safety profile with the same efficacy of higher doses (*i.e.* 70 mg twice-a-day). In a clinical trial with chronic myeloid leukemia patients, drug-related pleural effusion was more common with dasatinib (28%) than with imatinib (0.8%), with a higher incidence in patients over 65 years of age [60].

Most of the lung ADRs reported during imatinib therapy are related to fluid retention, a common side effect [64]. However, peripheral and periorbital oedema are far more frequent manifestations of fluid retention than are pleural or pericardial effusions and pulmonary oedema. Imatinib-induced pleural effusion appears to be dose dependent, with higher incidence in patients treated with 400 mg twice-a-day.

For the other BCR-ABL PKIs, the incidence of pleural effusion in clinical trials ranged from 9 to 12% for bosutinib [65], 2.1 to 9% for ponatinib [66] and less than 1% for nilotinib [67]. A

disproportionality analysis through data registered in the World Health Organization (WHO) safety report database (VigiBase[®]) showed that 29 of 33 PKIs included have significant RORs for pleural effusion with a highest value for dasatinib, bosutinib and ponatinib [12]. Besides, the study highlighted the role of Lyn (an off-target) in pleural effusion caused by PKIs through an immune-mediated process. Inhibition of Lyn could destabilize endothelial barrier leading to an increased endothelial permeability in pulmonary tissue [68].

In clinical trial with avapritinib, a PDGFR- α inhibitor, pleural effusions occurred in 12% of patients (2% grade 3 or worse) [69]. Cases of pleural effusion, some fatal, were reported during post-marketing surveillance with sunitinib, another PDGFR- α inhibitor [66].

Interstitial/parenchymal lung disease

Although it is uncommon, drug-induced interstitial lung disease (ILD) is one of the most serious off-target adverse reactions of PKIs and reported in many summaries of product characteristics (SmPCs) with varying frequency. The major concern is with PKIs indicated for non-small cell lung cancer cells such as anti-EGFR agents (*e.g.* erlotinib, gefitinib) and ALK inhibitors (*e.g.* crizotinib, ceritinib).

In a meta-analysis, the incidences of all-grade and high-grade ILD associated with EGFR-PKIs (gefitinib, erlotinib, and afatinib) in advanced non-small cell lung cancer cells were 1.6% and 0.9%, respectively, with a mortality rate of 13% [70]. Risk factors for EGFR-associated ILD include older age, male sex, smoking, history of pulmonary fibrosis, prior radiotherapy and anti-PD-1 monoclonal antibodies. The frequency of ILD-type ADRs in Japanese patients is much higher than in the rest of the world (broadly reported as 1.6–4.3 vs. 0.3–1.0%) suggesting a specific increased genetic susceptibility to ILD in the Japanese population [71]. The interval to onset of ILD is unpredictable, and its onset could be acute or insidious, and clinical manifestations are often severe enough to be potentially life-threatening. The molecular mechanism of PKI-induced pulmonary toxicity is currently unknown, and it appears increasingly likely that multiple factors are involved. Available evidence suggests that ILD is not an on-target effect resulting from inhibition of EGFR and not confined to a specific chemical structure of the PKI, especially in the lack of cross reactivity between EGFR-PKIs.

All drugs in the ALK family have been associated with ILD. The overall incidence of ALK inhibitor pneumonitis was 2.14% in patients with advanced non-small cell lung cancer cells. The

patients from Japanese cohorts had a higher incidence of ALK-inhibitor pneumonitis [72]. In clinical trials, crizotinib and ceritinib were associated with ILD by 3% and 4% respectively, and 1.5% and 3% with high grade. For brigatinib, incidence is higher with 9% all grade and close to 4% for severe grades. The clinical presentation differs from other ALK with a more rapid onset in the first one to nine days of treatment, and after suspension of brigatinib until pneumonitis resolution, approximately one-half are able to resume therapy [73]. Several hypotheses have been put forward to better clarify mechanisms responsible for this family with particular regard to crizotinib. It was hypothesized that crizotinib-associated ILD could emerge as a drug-related hypersensitivity pneumonitis, considering the relatively late onset potentially necessary for compound sensitization, the resolution after crizotinib discontinuation, and the reoccurrence after crizotinib reintroduction. The ILD could be interpreted as an effective immune antitumor response that was favoured or elicited by ALK inhibitor treatment [74].

In clinical a trial with idelalisib, a PI3K inhibitor, pneumonitis was reported in 4% of patients, including serious and fatal cases. Clinical manifestations included interstitial infiltrates and organizing pneumonia, and time to onset ranged from less than 1 month to 15 months. For alpelisib, incidence was 1.8%, and in patients with new or worsening respiratory symptoms or who are suspected of having pneumonitis, it is recommended to stop treatment immediately to evaluate the patient. In those with confirmed pneumonitis, treatment should be discontinued.

Post-marketing surveillance has revealed a small risk of potentially severe lung inflammation in patients treated with CDK4/6 inhibitors. A recent study using US pharmacovigilance data investigated the reporting of ILD with these drugs [75]. The results revealed a consistent increased reporting of ILD with CDK4/6 inhibitors as a class, which was consistent across the various sensitivity analyses, accounting for major biases and confounders, especially for abemaciclib.

ILD is a known side effect of inhibitors of mTOR. Mostly, ILD remains asymptomatic or mildly symptomatic with nonspecific clinical features, but infrequent fatal issues are reported [76]. In a meta-analysis of trials in which temsirolimus and everolimus were used to treat solid malignancies, the incidence rates of high grade and overall pulmonary toxicity were 3 and 12% respectively [77]. The exact mechanism or interplay of mechanisms leading to the development of ILD remains to be defined. Suggested mechanisms are either a direct toxic effect or immune-mediated mechanisms, considering mTOR inhibitors have several effects on the immune system [78].

ILD may have been underdiagnosed because it requires diagnostic testing, which may not have been undertaken in patients who developed respiratory symptoms during PKI therapy, possibly because the symptoms were assumed to be due to advanced non-small cell lung cancer cells. Furthermore, it can be difficult to distinguish progressive cancer from drug-induced ILD.

Other lung conditions

Cases of pneumothorax have been reported in patients treated with pazopanib, a PKI directed against the VEGF receptors [79].

PKIs used for autoimmune disease, comprised mostly of Janus kinase (JAK) and to a lesser extent, spleen tyrosine kinase (SyK) inhibitors, are associated with respiratory tract infections and increase the risk of non-opportunistic respiratory infections (upper and lower respiratory tract infections, influenza and pneumonia) when compared with placebo [80].

Overall, pulmonary ADRs with PKIs are relatedly frequent. The absence of specific signs and symptoms, as well as the absence of any clearly defined criteria for drug induced lung disease, makes diagnosis a real challenge. A better understanding of the underlying mechanisms will allow us to better prevent this risk and to adapt treatments according to the situation. In general, suspicion of significant drug-induced pulmonary complication justifies discontinuation of the PKI.

Hepatobiliary disorders

Hepatitis

PKIs have some degree of hepatotoxicity and many have been linked to cases of clinically apparent liver injury which can be severe and even fatal. Confirmation of PKI-induced hepatotoxicity can present challenges in the presence of hepatic metastasis and potential drug interactions. Onset of PKI-induced hepatotoxicity is usually within the first 2 months of initiating treatment, but may be delayed, and is usually reversible [81]. Some of the cases of liver injury attributed to the protein kinase antagonists had features of autoimmunity, suggesting that the liver injury may be caused by an immunologic reaction to metabolic products of the agent itself, rather than off-target activity of the inhibitor [82].

The incidence and severity of hepatotoxicity varies widely among PKI, but overall it is uncommon. Ghatalia *et al.* conducted a meta-analysis to determine the relative risk (RR) of hepatotoxicity with VEGFR PKI [83]. They found a statistical increase in RR of all-grade ALT, AST, ALP and bilirubin elevations (RR varying from 1.20 to 1.57) compared to the arm in the non-PKI

group. However, the incidence of liver failure was only 0.8%. The mechanism of VEGFR PKI induced hepatotoxicity has not been described but some hypothesize that the signal transduction pathways activated/inhibited during oxidative stress play a key role in drug-induced liver injury.

Hepatitis B virus reactivation and BCR-ABL PKIs

Several case reports and small studies have suggested that the use of BCR-ABL PKIs may be associated with an increased risk of hepatitis B virus reactivation in patients with the virus. Based on this initial data, in 2016, the European Medical Agency (EMA) highlighted the potential risk of hepatitis B virus reactivation associated with BCR-ABL PKI treatment and required that the product information be amended as reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL PKI. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome. Recently, a nested case-control study which included patients who entered a hepatitis B carrier cohort in Taiwan confirmed this risk [84]. This analysis revealed that BCR-ABL PKIs use during the previous 90 days was independently associated with a 56% higher risk of hepatitis B flare (adjusted rate ratio [aRR], 1.56, CI95% [1.11–2.20]). These results also showed a gender-specific difference, with a significantly increased risk of flare among women (aRR, 3.20, CI95% [1.70–6.03]) when the BCR-ABL PKI was used during the 60 days previous to the start of the study. Among the hypotheses raised, IPKs could target different pathways involved in the immune activation and the lymphocytes proliferation, leading to hepatitis B virus reactivation.

Pancreatitis

Cases of vemurafenib (a BRAF inhibitor) induced pancreatitis have been reported and a safety signal was published by the World Health Organization in 2014. The reactions generally occurred during the first two weeks of treatment. A retrospective French pharmacovigilance study found 22 cases of acute pancreatitis with anti-BRAF molecules [vemurafenib (n = 8), dabrafenib (n = 11) and encorafenib (n = 3)], suggesting a potential class effect [85,86]. This study highlights a dose-dependent mechanism with three cases of negative reintroduction with reduced dose.

Moreover, VEGF may play a role in regulating the cell cycle of acinar cells and maintaining adult pancreatic fenestrated capillaries; inhibition of VEGF leading to acinar cell apoptosis and

release of autodigestive enzymes. This hypothesis is reinforced by the cases described in the literature with VEGF inhibitory PKIs such as sorafenib or sunitinib [87]. Ghathalia *et al.* conducted a meta-analysis and found a significant 1.95-fold increase ($p = 0.042$, CI95% [1.02–3.70]) in the risk of all grades of pancreatitis with VEGFR PKIs compared to controls not receiving PKIs [88].

Musculoskeletal disorders

Musculoskeletal pain is well described during clinical trial with PKIs and up to 80% of chronic myeloid leukemia using PKIs reports this disorder [89]. Recently, it has been described that these pains, mainly the upper body joints, may occur upon discontinuation of the treatment constituting PKI withdrawal syndrome [90,91]. Indeed, over the past decade, many clinical trials in chronic myeloid leukemia have shown that the cessation of PKIs was achievable and safe. This withdrawal syndrome is a BCR-ABL inhibitor class effect and has been reported in 20 to 40% of patients attempting treatment free remission [91]. The syndrome appeared within two months after PKI discontinuation and lasted for several months (median: 7 months), although some patients experienced these pains for longer. The duration of PKI treatment and history of osteoarticular symptoms have been identified as risk factors for the occurrence of this withdrawal syndrome.

Rhabdomyolysis is an adverse effect to be watchful for. Cases have been reported in clinical trials and post-marketing with MEK inhibitors (*e.g.* cobimetinib, tramatenib), used in the treatment of melanoma [92].

This overview of the ADRs associated with PKIs is obviously not exhaustive and the safety profile of these drugs is still being actively monitored.

Conclusion

Overall, almost 20 years after the development of first PKIs, preclinical, clinical and epidemiological research on their ADRs made it possible to identify a different safety profile, probably due to different target profiles. Identification of these targets, on- and off-targets, has improved the global understanding of the pathophysiological mechanisms underlying the onset of ADRs with these drugs. However, knowledge of the safety profile of PKIs is not fully complete and active

pharmacovigilance of this large class of drugs should be continued. This is supported by the drug safety communications about PKIs, regularly issued by the drug agencies of various countries; for example in 2021 regarding increased risk of serious heart-related ADRs, cancer, blood clots, and death for tofacitinib, JAK inhibitor that treat certain chronic inflammatory conditions. Further collaboration between basic and translational scientists will permit investigations to elucidate the mechanism of the ADRs and to define patients at risk, such that preventive and treatment efforts can be focused on these high-risk patients.

Disclosure of interest

Authors have no competing interest to declare.

Journal Pre-proof

References

- [1] Stokes MP, Farnsworth CL, Moritz A, Silva JC, Jia X, Lee KA, et al. PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS. *Mol Cell Proteomics* 2012;11:187–201.
- [2] Bournez C, Carles F, Peyrat G, Aci-Sèche S, Bourg S, Meyer C, et al. Comparative assessment of protein kinase inhibitors in public databases and in PKIDB. *Molecules* 2020;25:3226.
- [3] Carles F, Bourg S, Meyer C, Bonnet P. PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials. *Molecules* 2018;23:908.
- [4] Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. *Pharmacol Res* 2020;152:104609.
- [5] Zarrin AA, Bao K, Lupardus P, Vucic D. Kinase inhibition in autoimmunity and inflammation. *Nat Rev Drug Discov* 2021;20:39–63.
- [6] Blanc J, Geney R, Menet C. Type II kinase inhibitors: an opportunity in cancer for rational design. *Anticancer Agents Med Chem* 2013;13:731–47.
- [7] Roskoski R. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). *Pharmacol Res* 2021;165:105422.
- [8] Ghoreschi K, Laurence A, O’Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? *Nat Immunol* 2009;10:356–60.
- [9] Gridling M, Ficarro SB, Breitwieser FP, Song L, Parapatics K, Colinge J, et al. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. *Mol Cancer Ther* 2014;13:2751–62.
- [10] Gougis P, Wassermann J, Spano JP, Keynan N, Funck-Brentano C, Salem JE. Clinical pharmacology of anti-angiogenic drugs in oncology. *Crit Rev Oncol Hematol* 2017;119:75–93.
- [11] Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. *Br J Clin Pharmacol* 2017;83:1544–55.
- [12] Mahé J, de Campaigno EP, Chené AL, Montastruc JL, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from Vigibase: Pleural adverse drugs reactions and protein kinase inhibitors. *Br J Clin Pharmacol* 2018;84:2373–83.

- [13] Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, et al. Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. *Eur Respir J* 2019;53: 1802472.
- [14] Montastruc JL, Benevent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M, et al. What is pharmacoepidemiology? Definition, methods, interest and clinical applications. *Therapies* 2019;74:169–74.
- [15] Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. *Nat Med* 2006;12:908–16.
- [16] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019;69:7–34.
- [17] Moslehi JJ, Deining M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. *J Clin Oncol* 2015;33:4210–8.
- [18] Cautela J, Lalevéé N, Ammar C, Ederhy S, Peyrol M, Debourdeau P, et al. Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. *Int J Cardiol* 2016;224:366–75.
- [19] Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem J, Barlesi F, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines. *J Am Heart Assoc* 2020;9:e018403..
- [20] Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J. Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care. *Arterioscler Thromb Vasc Biol* 2020;40:301–8.
- [21] Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies. *J Am Coll Cardiol* 2015;66:1160–78.
- [22] Mäki-Petäjä KM, McGeoch A, Yang LL, Hubsch A, McEniery CM, Meyer PAR, et al. Mechanisms underlying vascular endothelial growth factor receptor inhibition–induced hypertension: the HYPАЗ trial. *Hypertension* 2021;77:1591–9.
- [23] Collins T, Gray K, Bista M, Skinner M, Hardy C, Wang H, et al. Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension: Effect of VEGFR-2 inhibition on blood pressure. *Br J Pharmacol* 2018;175:618–30.
- [24] Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. *Semin Nephrol* 2010;30:591–601.
- [25] de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. *Hypertens Dallas Tex* 1979 2012;60:607–15.

- [26] FDA. Potential signals of serious risks/new safety information identified by the FDA adverse event reporting system (FAERS). October - December 2018. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/october-december-2018-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>. [Accessed 29 October 2021].
- [27] Dörks M, Jobski K, Herget- Rosenthal S, Hoffmann F, Douros A. Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis. *Pharmacol Res Perspect* 2021;9: e00707.
- [28] Jain P, Kantarjian H, Boddu PC, Noguera-González GM, Verstovsek S, Garcia-Manero G, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. *Blood Adv* 2019;3:851–61.
- [29] Wu MD, Moslehi JJ, Lindner JR. Arterial thrombotic complications of tyrosine kinase inhibitors. *Arterioscler Thromb Vasc Biol* 2021;41:3–10.
- [30] Müller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, et al. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. *Crit Rev Oncol Hematol* 2017;120:52–9.
- [31] Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. *Clin Cancer Res* 2008;14:352–9.
- [32] Deb S, Boknäs N, Sjöström C, Tharmakulanathan A, Lotfi K, Ramström S. Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications? *Cancer Med* 2020;9:313–23.
- [33] Sener Y, Okay M, Aydın S, Buyukasik Y, Akbiyik F, Dikmen ZG. TKI-related platelet dysfunction does not correlate with bleeding in patients with chronic phase-chronic myeloid leukemia with complete hematological response. *Clin Appl Thromb Hemost* 2019;25:1076029619858409. doi: 10.1177/1076029619858409.
- [34] Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. *Circulation* 2008;118:84–95.
- [35] Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. *Cancer Treat Rev* 2017;53:120–7.
- [36] Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. *NPJ Precis Oncol* 2018;2:13.

- [37] Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. *Int J Cancer* 2020;147:3160–7.
- [38] Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. *Cardiovasc Res* 2019;115:895–903.
- [39] Woosley R, Heise C, Gallo T, Tate J, Woosley D, Romero K. QTdrugs List, Inc. 1457 E. Desert Garden Dr., Tucson, AZ 85718. 2013. <https://www.CredibleMeds.org>. [Accessed 29 October 2021].
- [40] Porta- Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, Diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. *J Am Heart Assoc* 2017;6: e007724.
- [41] Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N Engl J Med* 2013;369:32–42.
- [42] Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. *Circulation* 2020;142:2443–55.
- [43] Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. *J Am Coll Cardiol* 2019;74:1667–78.
- [44] Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. *Bone Marrow Transplant* 2009;43:967–8.
- [45] Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. *Leuk Res* 2009;33:861–4.
- [46] Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019;53:1801913.
- [47] Hickey PM, Thompson AAR, Charalampopoulos A, Elliot CA, Hamilton N, Kiely DG, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. *Eur Respir J* 2016;48:1514–6.
- [48] Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, et al. Translating research into improved patient care in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2017;195:583–95.
- [49] Humbert M, Guignabert C, Bonnet S, Dorfmueller P, Klinger JR, Nicolls MR, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. *Eur Respir J* 2019;53:1801887.

- [50] Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, et al. Optimising experimental research in respiratory diseases: an ERS statement. *Eur Respir J* 2018;51:1702133.
- [51] Low AT, Howard L, Harrison C, Tulloh RMR. Pulmonary arterial hypertension exacerbated by ruxolitinib. *Haematologica* 2015;100:e244-245.
- [52] Chabrol A, Mayenga M, Hamid AM, Friard S, Salvator H, Doubre H, et al. Lorlatinib - Induced pulmonary arterial hypertension. *Lung Cancer Amst Neth* 2018;120:60–1.
- [53] Breccia M, Loglisci G, Salaroli A, Serrao A, Alimena G. Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. *Leuk Res* 2012;36:e66-67.
- [54] Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. *Haematologica* 2014;99:1197–203.
- [55] Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. *Circulation* 2019;139:e579–e602.
- [56] Lutz SZ, Ullrich A, Häring H-U, Ullrich S, Gerst F. Sunitinib specifically augments glucose-induced insulin secretion. *Cell Signal* 2017;36:91–7.
- [57] Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? *Nat Rev Clin Oncol* 2017;14:141–54.
- [58] Cirimi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS). *Cancers* 2020;12:826.
- [59] Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new--An evolving avenue. *Circulation* 2016;133:1272–89.
- [60] Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. *J Clin Oncol* 2016;34:2333–40.
- [61] Brixey AG, Light RW. Pleural effusions due to dasatinib. *Curr Opin Pulm Med* 2010;16:351–6.
- [62] Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2010;362:2260–70.
- [63] Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in

- chronic phase and efficacy is unaffected in patients who develop pleural effusion. *Cancer* 2010;116:377–86.
- [64] Breccia M, D’Elia GM, D’Andrea M, Latagliata R, Alimena G. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. *Eur J Haematol* 2005;74:89–90.
- [65] Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim D-W, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. *Blood* 2012;119:3403–12.
- [66] IBM Micromedex® 1.0 (Healthcare Series), (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. 2021. <http://www.micromedexsolutions.com/> [Accessed 29 October 2021].
- [67] Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *Lancet Oncol* 2011;12:841–51.
- [68] Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. *Target Oncol* 2009;4:99–105.
- [69] Heinrich MC, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. *Lancet Oncol* 2020;21:935–46.
- [70] Qi WX, Sun YJ, Shen Z, Yao Y. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. *J Chemother* 2015;27:40–51.
- [71] Shah RR. Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas. *Drug Saf* 2016;39:1073–91.
- [72] Suh CH, Kim KW, Pyo J, Hatabu H, Nishino M. The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. *Lung Cancer Amst Neth* 2019;132:79–86.
- [73] Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase ii trial. *J Clin Oncol* 2017;35:2490–8.
- [74] Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M. Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. *Clin Lung Cancer* 2018;19:e151–e161.

- [75] Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. *Breast Cancer Res Treat* 2021;186:219–27.
- [76] Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. *Eur J Cancer Oxf Engl* 2006;42:1875–80.
- [77] Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. *Acta Oncol* 2012;51:873–9.
- [78] Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CML, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. *Int J Cancer* 2016;138:2312–21.
- [79] Verschoor AJ, Gelderblom H. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. *Clin Sarcoma Res* 2014;4:14.
- [80] Khoo JK, Barnes H, Key S, Glaspole IN, Östör AJ. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. *Rheumatology (Oxford)* 2020;59:2217–25.
- [81] Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. *Drug Saf* 2013;36:491–503.
- [82] National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): 2012-. <https://www.ncbi.nlm.nih.gov/books/NBK547852/>. [Accessed 29 October 2021].
- [83] Ghatalia P, Je Y, Mouallem NE, Nguyen PL, Trinh QD, Sonpavde G, et al. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol* 2015;93:257–76.
- [84] Wang LY, Chu SC, Lo Y, Yang YY, Chan KA. Association of Bcr-Abl tyrosine kinase inhibitors with hepatitis B virus reactivation requiring antiviral treatment in Taiwan. *JAMA Netw Open* 2021;4:e214132.
- [85] Quarteroni L. Anti-BRAF molecules (ABM)-induced acute pancreatitis. Analysis of class-effect positive rechallenge from the French Pharmacovigilance Database (FPVD). *Fundam Clin Pharmacol* 2021:119–20.
- [86] Moore N, Berdaï D, Blin P, Droz C. Pharmacovigilance - The next chapter. *Therapies* 2019;74:557–67.

- [87] Sevin A, Chen A, Atkinson B. Tyrosine kinase inhibitor induced pancreatitis. *J Oncol Pharm Pract* 2013;19:257–60.
- [88] Ghatalia P, Morgan CJ, Choueiri TK, Rocha P, Naik G, Sonpavde G. Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. *Crit Rev Oncol Hematol* 2015;94:136–45.
- [89] Kekäle M, Peltoniemi M, Airaksinen M. Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. *Patient Prefer Adherence* 2015;9:1733–40.
- [90] Kota V, Atallah E. Musculoskeletal pain in patients with chronic myeloid leukemia after tyrosine kinase inhibitor therapy cessation. *Clin Lymphoma Myeloma Leuk* 2019;19:480–7.
- [91] Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. *Br J Haematol* 2019;187:337–46.
- [92] Muto Y, Ng W, Namikawa K, Takahashi A, Tsutsumida A, Nishida M, et al. Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report. *Melanoma Res* 2018;28:151–4.




Figure 1. Kinome phylogenetic tree representing the pharmacological targets of clinically developed kinase inhibitors.

According to Cortellis database, all of the kinases being targeted by at least one inhibitor have been highlighted. Each circle for each protein kinase reflects the total number of inhibitors known to have an action on this target. All the drugs' mechanisms have been taken into account, i.e. for multiple mechanisms, the molecule has been assigned to each of its targets as well as its state of development. The greener the circle, the greater the number of inhibitors granted marketing authorisation. Conversely, the redder the circle is, the more inhibitors there are that have failed during clinical development. Grey circles represent targets for which inhibitors are all under development. *This kinase dendrogram were created using the interactive web application CORAL.*




Figure 2. Kinome phylogenetic tree representing the target profiles of dasatinib and sunitinib.

Each circle for each protein kinase represents the interactions observed for the two kinase inhibitors based on data from Karaman *et al.*. Only affinities less than 1000 nM are shown. Larger circles indicate higher affinity for the kinase. The yellow circles represent common targets while the green and blue circles correspond to the specific targets of dasatinib and sunitinib respectively. *This kinase dendrogram were created from the interactive web application CORAL.*

Journal Pre-proof




Figure 3. Major adverse drug reactions (ADRs) induced by protein kinase inhibitors.